Replies to post #627660 on NorthWest Biotherapeutics Inc (NWBO)

[Roman516]

What is Overall Survival OS data?

Overall Survival (OS)
Overall survival, or OS, measures how long patients, who undergo a certain treatment regimen, live compared to patients who are in a control group (i.e., taking either another drug or an inactive treatment, known as a placebo). If a clinical trial demonstrates improved OS, it provides evidence of the drug’s value in prolonging a cancer patient’s life. OS is a strong and precise endpoint, as it requires having more patients and longer follow-ups compared to other clinical trial endpoints. Given all this, OS is often considered the “gold standard” for measuring the clinical benefits of a cancer drug.
Overall Survival (OS)
• Measures how long patients in the treatment group live compared to a controlled group.
• Is known as the gold standard in oncology clinical trials. “
Source
https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/clinical-trial-endpoints-in-cancer-research-four-terms-you-should-know-09242018.html#
https://seekingalpha.com/article/4560104-northwest-biotherapeutics-stock-data-is-done-just-wait-for-approval
https://investmentu.com/nwbo-stock/

[jon_k84]

I don't really get your point. What part of 'there are many people form the trial still alive today' do you not understand?

I do believe that Dr Liau said in an interview/talk that everyone who got the placebo and didn't cross over is dead. Seems like a pretty stark contrast.